Display Settings:

Format

Send to:

Choose Destination

    Genomics. 1991 Sep;11(1):206-11.

    In vitro mutagenesis helps to unravel the biological consequences of aspartylglucosaminuria mutation.

    Ikonen E, Enomaa N, Ulmanen I, Peltonen L.

    Laboratory of Molecular Genetics, National Public Health Institute, Helsinki, Finland.

    Aspartylglucosaminuria (AGU) is a lysosomal storage disease resulting in severe mental retardation. We have recently reported that mutations in the aspartylglucosaminidase (AGA) locus are responsible for this disease. About 90% of reported AGU cases are found in Finland, and we have shown that the vast majority (98%) of AGU alleles in this isolated population contain two point mutations located 5 bp apart. We expressed these Arg161----Gln and Cys163----Ser mutations separately in vitro and demonstrated that deficient enzyme activity is caused by the Cys163----Ser mutation, whereas the Arg161----Gln substitution represents a rare polymorphism. Further analyses of in vitro expressed AGA proteins and the enzyme purified from an AGU patient revealed that Cys163 participates in and S-S bridge. The absence of this covalent cross-link in the mutated protein most probably results in disturbed folding of the polypeptide chain and a consequent decrease in its intracellular stability.

    PMID: 1765378 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read